How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Female Hypoactive Sexual Desire Disorder Therapeutics Market
- By Therapeutic Class: Phosphodiesterase Inhibitors, Hormonal Therapies, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, Combination Therapies
- By Route of Administration: Oral, Topical, Intranasal, Injectable
- By Patient Demographics: Premenopausal Women, Postmenopausal Women, Women with Surgical Menopause, Women with Comorbid Psychological Conditions
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Clinics
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Phosphodiesterase Inhibitors leads By Therapeutic Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 270 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 13 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the Female Hypoactive Sexual Desire Disorder Therapeutics Market report
A complete, evidence-based study - 11 chapters and 113 sections covering market size, segmentation across 4 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Class 5
Route of Administration 4
Patient Demographics 4
Distribution Channel 4
Companies profiled
Sprout Pharmaceuticals (a Pfizer company)
Bayer AG
Endo International plc
HRA Pharma (a Pfizer company)
AMAG Pharmaceuticals
Mylan N.V. (now part of Viatris)
AbbVie Inc.
Mitsubishi Tanabe Pharma Corporation
TherapeuticsMD Inc.
Palatin Technologies Inc.
Addex Therapeutics
Revive Therapeutics Ltd.
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Sprout Pharmaceuticals (a Pfizer company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Endo International plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →HRA Pharma (a Pfizer company)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →AMAG Pharmaceuticals
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mitsubishi Tanabe Pharma Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →TherapeuticsMD Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Palatin Technologies Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Addex Therapeutics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Revive Therapeutics Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Indivior PLC
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$3,863M by 2033 · 3.8% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Phosphodiesterase Inhibitors55.2
- Hormonal Therapies9.8
- Selective Estrogen Receptor Modulators (SERMs)12.6
- Dopamine Agonists7.2
- Combination Therapies15.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$949.2M → $1,414M · 5.1%
Europe$661.6M → $858.8M · 3.3%
Asia Pacific$604.0M → $905.9M · 5.2%
Latin America$373.9M → $454.4M · 2.5%
Middle East and Africa$287.6M → $388.5M · 3.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →3.702026
3.732027
3.722028
3.732029
3.762030
3.772031
3.782032
3.792033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Sprout Pharmaceuticals (a Pfizer company)12.2
- Bayer AG13.2
- Endo International plc14.0
- HRA Pharma (a Pfizer company)9.9
- AMAG Pharmaceuticals11.1
- Mylan N.V. (now part of Viatris)11.6
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Class16.1%
Route of Administration37.6%
Patient Demographics21.5%
Distribution Channel24.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America35.2
- Europe21.4
- Asia Pacific22.5
- Latin America11.3
- Middle East and Africa9.7
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Sprout Pharmaceuticals (a Pfizer company) | 84 | 94 | 97 | 81 | 80 | 90 | 88 |
| Bayer AG | 84 | 93 | 74 | 74 | 68 | 72 | 78 |
| Endo International plc | 71 | 75 | 85 | 84 | 74 | 84 | 79 |
| HRA Pharma (a Pfizer company) | 79 | 71 | 75 | 80 | 58 | 68 | 72 |
| AMAG Pharmaceuticals | 65 | 53 | 63 | 62 | 72 | 76 | 65 |
| Mylan N.V. (now part of Viatris) | 49 | 53 | 56 | 65 | 69 | 52 | 57 |
| AbbVie Inc. | 57 | 41 | 40 | 58 | 65 | 43 | 51 |
| Mitsubishi Tanabe Pharma Corporation | 53 | 57 | 37 | 40 | 50 | 54 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Sprout Pharmaceuticals (a Pfizer company)
- Bayer AG
- Endo International plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Sprout Pharmaceuticals (a Pfizer company) | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Bayer AG | ◐ | ◐ | ◐ | ◐ | − | ◐ |
| Endo International plc | ◐ | ◐ | ◐ | ◐ | ◐ | ✓ |
| HRA Pharma (a Pfizer company) | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| AMAG Pharmaceuticals | ◐ | ◐ | ✓ | − | ◐ | ◐ |
| Mylan N.V. (now part of Viatris) | − | − | ◐ | ✓ | ◐ | ◐ |
| AbbVie Inc. | − | − | − | ◐ | − | − |
| Mitsubishi Tanabe Pharma Corporation | ◐ | ◐ | − | − | ◐ | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Sprout Pharmaceuticals (a Pfizer company)88
2Endo International plc79
3Bayer AG78
4HRA Pharma (a Pfizer company)72
5AMAG Pharmaceuticals65
6Mylan N.V. (now part of Viatris)57
7AbbVie Inc.51
8Mitsubishi Tanabe Pharma Corporation49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Sprout Pharmaceuticals (a Pfizer company)Bayer AGEndo International plc
Challenger1
Strong scale, closing on the leaders.
HRA Pharma (a Pfizer company)
Contender2
Focused players with pockets of strength.
AMAG PharmaceuticalsMylan N.V. (now part of Viatris)
Niche2
Specialists in a single segment or region.
AbbVie Inc.Mitsubishi Tanabe Pharma Corporation
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Class in North America, then scale across Female Hypoactive Sexual Desire Disorder Therapeutics Market — a $382M beachhead inside a $7.30B market.
Beachhead (SOM)$382Mobtainable near-term
Serviceable (SAM)$2.59Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion91 fit
Phosphodiesterase Inhibitors
Best fit — highest urgency & budget in Therapeutic Class.
Economic buyer76 fit
Hormonal Therapies
Strong fit — clear ROI and a fast path to value.
End user64 fit
Selective Estrogen Receptor Modulators (SERMs)
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Route of Administration & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Patient Demographics
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales42%
Partner / channel27%
Digital / self-serve22%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Female Hypoactive Sexual Desire Disorder Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified41%
Sales qualified25%
Evaluation15%
Closed-won6%
$10.7KCAC
$42KLTV
4.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Female Hypoactive Sexual Desire Disorder Therapeutics Market is a high-growth opportunity — $6.12B by 2033, compounding at 11.0%.
TAM · 2025$2.65Btoday
TAM · 2033$6.12Bforecast
CAGR11.0%2027–2033
Cumulative$37.6Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$6.12BTotal addressable market
SAM$2.40BServiceable available market
SOM$494MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →11.0% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Class moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$6.12BLarge & growingTAM by 2033 at 11.0% CAGR
$2.40BServiceable nowreachable with today’s model
$494MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.77BBear7.2% CAGR
$6.12BBase11.0% CAGR
$7.83BBull14.5% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Route of Administration optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Female Hypoactive Sexual Desire Disorder Therapeutics Market — a $10.5B market by 2033. Plan: grow share from 8.4% to 15.3%.
Market size · 2033$10.5Btotal addressable
Market CAGR10.6%2027–2033
Target share15.3%from 8.4% today
Revenue ambition$1.60Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.4% | 15.3% | At risk |
| Revenue | $836M | $1.60B | Behind |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Behind |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 37.5% | 44.9% | Ahead |
| Customer retention | 91.7% | 95.9% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Route of Administration capability
A defensible second engine — invest in Route of Administration to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Route of Administration
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $167M capacity & capability investment
- Greenlight bolt-on M&A in Route of Administration
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Female Hypoactive Sexual Desire Disorder Therapeutics Market conversation — a $12.1B market you can size, segment and defend in minutes.
Market size · 2033$12.1Btotal opportunity
Growth11.4%CAGR to 2033
Addressable buyers942+accounts in scope
Typical ROI4.9×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Class
Goal Grow share in Therapeutic Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.9×return on cost, year one
< 3 mopayback period
$99K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
Sprout Pharmaceuticals (a Pfizer company)Bayer AGEndo International plcHRA Pharma (a Pfizer company)AMAG PharmaceuticalsMylan N.V. (now part of Viatris)AbbVie Inc.Mitsubishi Tanabe Pharma Corporation+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Female Hypoactive Sexual Desire Disorder Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Female Hypoactive Sexual Desire Disorder Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Beta Catenin Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportErythropoietin Drugs Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportGlycogen Synthase Kinase 3 Beta Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCritical Limb Ischemia Drug Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportAdrenocorticotropic Hormone Receptor Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportLiver Disease Treatment Market
Market size, share, segmentation and regional forecast.
$376M market · 2025 base year
View reportPlaque Disclosing Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportMarburgvirus Infection Market
Market size, share, segmentation and regional forecast.
$4.9B market · 2025 base year
View reportAxial Spondyloarthritis Drugs Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportGlutaraldehyde (Pharm Grade) Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportBotulinum Toxin Injection Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportNifedipine Market
Market size, share, segmentation and regional forecast.
$356M market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.